|
Gene: ACSL5 |
Gene summary for ACSL5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ACSL5 | Gene ID | 51703 |
Gene name | acyl-CoA synthetase long chain family member 5 | |
Gene Alias | ACS2 | |
Cytomap | 10q25.2 | |
Gene Type | protein-coding | GO ID | GO:0001676 | UniProtAcc | Q9ULC5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51703 | ACSL5 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.42e-05 | 4.40e-01 | -0.1954 |
51703 | ACSL5 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.18e-02 | 5.77e-01 | -0.059 |
51703 | ACSL5 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.28e-03 | 5.12e-01 | 0.281 |
51703 | ACSL5 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 7.29e-03 | 5.77e-01 | 0.3859 |
51703 | ACSL5 | A015-C-203 | Human | Colorectum | FAP | 1.59e-27 | -2.77e-01 | -0.1294 |
51703 | ACSL5 | A015-C-204 | Human | Colorectum | FAP | 2.65e-05 | -3.18e-01 | -0.0228 |
51703 | ACSL5 | A014-C-040 | Human | Colorectum | FAP | 4.68e-04 | -3.99e-01 | -0.1184 |
51703 | ACSL5 | A002-C-201 | Human | Colorectum | FAP | 3.92e-15 | -3.85e-01 | 0.0324 |
51703 | ACSL5 | A002-C-203 | Human | Colorectum | FAP | 9.19e-05 | 5.16e-02 | 0.2786 |
51703 | ACSL5 | A001-C-119 | Human | Colorectum | FAP | 4.13e-05 | -3.27e-02 | -0.1557 |
51703 | ACSL5 | A001-C-108 | Human | Colorectum | FAP | 5.89e-18 | -1.27e-01 | -0.0272 |
51703 | ACSL5 | A002-C-205 | Human | Colorectum | FAP | 1.20e-21 | -3.63e-01 | -0.1236 |
51703 | ACSL5 | A001-C-104 | Human | Colorectum | FAP | 5.17e-05 | -5.45e-02 | 0.0184 |
51703 | ACSL5 | A015-C-006 | Human | Colorectum | FAP | 1.10e-13 | -3.41e-01 | -0.0994 |
51703 | ACSL5 | A015-C-106 | Human | Colorectum | FAP | 3.32e-13 | -1.65e-02 | -0.0511 |
51703 | ACSL5 | A002-C-114 | Human | Colorectum | FAP | 3.13e-18 | -2.92e-01 | -0.1561 |
51703 | ACSL5 | A015-C-104 | Human | Colorectum | FAP | 1.71e-36 | -1.70e-01 | -0.1899 |
51703 | ACSL5 | A001-C-014 | Human | Colorectum | FAP | 1.66e-15 | -1.81e-01 | 0.0135 |
51703 | ACSL5 | A002-C-016 | Human | Colorectum | FAP | 1.25e-27 | -3.42e-01 | 0.0521 |
51703 | ACSL5 | A015-C-002 | Human | Colorectum | FAP | 2.20e-12 | -5.26e-01 | -0.0763 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
GO:0009152 | Colorectum | AD | purine ribonucleotide biosynthetic process | 64/3918 | 169/18723 | 3.09e-07 | 1.22e-05 | 64 |
GO:0009260 | Colorectum | AD | ribonucleotide biosynthetic process | 66/3918 | 182/18723 | 1.25e-06 | 4.02e-05 | 66 |
GO:0046390 | Colorectum | AD | ribose phosphate biosynthetic process | 67/3918 | 190/18723 | 3.21e-06 | 9.05e-05 | 67 |
GO:0006164 | Colorectum | AD | purine nucleotide biosynthetic process | 66/3918 | 191/18723 | 8.22e-06 | 1.97e-04 | 66 |
GO:0072522 | Colorectum | AD | purine-containing compound biosynthetic process | 68/3918 | 200/18723 | 1.12e-05 | 2.55e-04 | 68 |
GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
GO:1901293 | Colorectum | AD | nucleoside phosphate biosynthetic process | 80/3918 | 256/18723 | 6.31e-05 | 1.05e-03 | 80 |
GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
GO:0009165 | Colorectum | AD | nucleotide biosynthetic process | 79/3918 | 254/18723 | 8.33e-05 | 1.30e-03 | 79 |
GO:0033865 | Colorectum | AD | nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
GO:0033875 | Colorectum | AD | ribonucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
GO:0034032 | Colorectum | AD | purine nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04714 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
hsa04216 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
hsa00071 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
hsa047141 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
hsa042161 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
hsa000711 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
hsa047144 | Colorectum | MSS | Thermogenesis | 113/1875 | 232/8465 | 1.52e-19 | 4.62e-18 | 2.83e-18 | 113 |
hsa042162 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
hsa000714 | Colorectum | MSS | Fatty acid degradation | 17/1875 | 43/8465 | 7.50e-03 | 2.86e-02 | 1.75e-02 | 17 |
hsa047145 | Colorectum | MSS | Thermogenesis | 113/1875 | 232/8465 | 1.52e-19 | 4.62e-18 | 2.83e-18 | 113 |
hsa042163 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
hsa000715 | Colorectum | MSS | Fatty acid degradation | 17/1875 | 43/8465 | 7.50e-03 | 2.86e-02 | 1.75e-02 | 17 |
hsa047148 | Colorectum | FAP | Thermogenesis | 70/1404 | 232/8465 | 1.38e-07 | 3.08e-06 | 1.87e-06 | 70 |
hsa042164 | Colorectum | FAP | Ferroptosis | 18/1404 | 41/8465 | 3.49e-05 | 3.65e-04 | 2.22e-04 | 18 |
hsa000716 | Colorectum | FAP | Fatty acid degradation | 15/1404 | 43/8465 | 2.73e-03 | 1.23e-02 | 7.50e-03 | 15 |
hsa047149 | Colorectum | FAP | Thermogenesis | 70/1404 | 232/8465 | 1.38e-07 | 3.08e-06 | 1.87e-06 | 70 |
hsa042165 | Colorectum | FAP | Ferroptosis | 18/1404 | 41/8465 | 3.49e-05 | 3.65e-04 | 2.22e-04 | 18 |
hsa000717 | Colorectum | FAP | Fatty acid degradation | 15/1404 | 43/8465 | 2.73e-03 | 1.23e-02 | 7.50e-03 | 15 |
hsa042166 | Colorectum | CRC | Ferroptosis | 13/1091 | 41/8465 | 1.36e-03 | 1.08e-02 | 7.33e-03 | 13 |
hsa01212 | Colorectum | CRC | Fatty acid metabolism | 14/1091 | 57/8465 | 1.17e-02 | 4.99e-02 | 3.38e-02 | 14 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACSL5 | SNV | Missense_Mutation | c.1246N>T | p.Asp416Tyr | p.D416Y | Q9ULC5 | protein_coding | deleterious(0) | probably_damaging(0.951) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ACSL5 | SNV | Missense_Mutation | c.956N>T | p.Gly319Val | p.G319V | Q9ULC5 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ACSL5 | SNV | Missense_Mutation | c.1693N>A | p.Glu565Lys | p.E565K | Q9ULC5 | protein_coding | tolerated(0.05) | benign(0.104) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ACSL5 | SNV | Missense_Mutation | novel | c.86N>G | p.Glu29Gly | p.E29G | Q9ULC5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.726) | TCGA-D5-6922-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
ACSL5 | SNV | Missense_Mutation | c.676N>A | p.Ala226Thr | p.A226T | Q9ULC5 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ACSL5 | SNV | Missense_Mutation | rs186230656 | c.937N>A | p.Val313Ile | p.V313I | Q9ULC5 | protein_coding | tolerated(1) | benign(0.005) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACSL5 | SNV | Missense_Mutation | c.28N>A | p.Trp10Arg | p.W10R | Q9ULC5 | protein_coding | deleterious_low_confidence(0.04) | benign(0.001) | TCGA-DT-5265-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ACSL5 | SNV | Missense_Mutation | rs749931911 | c.1783N>A | p.Asp595Asn | p.D595N | Q9ULC5 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACSL5 | SNV | Missense_Mutation | novel | c.2214N>T | p.Gln738His | p.Q738H | Q9ULC5 | protein_coding | deleterious(0.03) | possibly_damaging(0.785) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACSL5 | SNV | Missense_Mutation | rs759733603 | c.1226N>A | p.Arg409Gln | p.R409Q | Q9ULC5 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |